Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Quadrivalent Influenza Vaccine Gains FDA Approval

XTALKS VITALS NEWS

Vaccine

According to a press release issued by the company, Flublok Quadrivalent is the only influenza vaccine approved by the FDA which contains a high antigen content.

Tweetables from this article:

Tweet: #Clinicaltrial: adults given the Flublok Quadrivalent #vaccine had a 40 percent lesser chance of contracting #influenza http://ctt.ec/9dkcZ+ #Clinicaltrial: adults given the Flublok Quadrivalent #vaccine had a 40 percent lesser chance of contracting #influenza.

Share this!

October 13, 2016 | by Sarah Hand, M.Sc.

Protein Sciences Corporation’s quadrivalent Flublok influenza vaccine has been approved by the US Food and Drug Administration (FDA). This latest version of the influenza vaccine protects against three of the same strains found in the previous trivalent Flublok, in addition to a fourth B strain of the virus.

According to a press release issued by the company, Flublok Quadrivalent is the only influenza vaccine approved by the FDA which contains a high antigen content. The vaccine is well-suited to the elderly and those with a compromised immune system as it contains three times more of the active ingredient, compared to other approved quadrivalent vaccines.



To test the efficacy of Flublok Quadrivalent in people over the age of 50, Protein Sciences conducted a 9,000 participant clinical trial. They found that adults given the Flublok Quadrivalent had a 40 percent lesser chance of contracting influenza, compared to those that were administered the leading quadrivalent vaccine.

“The U.S. has been trending toward the use of quadrivalent flu vaccines in recent years,” said Manon Cox, President and CEO of Protein Sciences Corporation. “We are pleased to bring Flublok Quadrivalent to market to give consumers additional options, especially seniors who have no other high antigen content quadrivalent vaccine available to them. We are looking forward to launching the vaccine next year and, in the meantime, continuing to make trivalent Flublok available this year.”

Flubok Quadrivalent has been approved by the FDA for use in patients 18 and older and will be available in early 2017. As a protein-based vaccine, it contains no infectious influenza virus, antibiotics, egg products or preservatives. Approved in 2013, the trivalent version of the vaccine is available in pharmacies throughout the US.


Keywords: Influenza, Vaccine, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New PARP Inhibitor Drug Approved to Treat Women with Recurrent Ovarian Cancer

March 29, 2017 - The US Food and Drug Administration (FDA) has approved Zejula (niraparib) as a maintenance treatment for women with certain types of recurrent cancers, including epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Featured In: Pharmaceutical News


Nektar’s Opioid Analgesic Meets Endpoints in Phase III Clinical Trial

March 28, 2017 - Nektar Therapeutics has announced that their opioid analgesic has met both its primary and secondary endpoint in a recent Phase III efficacy study.

Featured In: Clinical Trials News


Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


Natural History vs. Registry Studies in Rare Disease


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act


Copyright © 2016-2017 Honeycomb Worldwide Inc.